CG Oncology (CGON) Following Q3 Earnings Has A Stronger Case For Its Valuation

Simply Wall St · 1d ago

Why CG Oncology Stock Is Back In Focus After Q3 Earnings

CG Oncology (CGON) is back on radar after third quarter results showed revenue of US$1.6 million, a narrower loss than many expected, and fresh updates on late stage bladder cancer programs.

The latest 1-day share price return of 17.27% and 7-day share price return of 17.49% put CG Oncology back on traders’ screens. However, the 90-day share price return of 1.19% shows earlier momentum had cooled, even as the year-to-date gain of 81.84% and 1-year total shareholder return of 91.51% keep the longer view firmly in positive territory.

Spot fresh momentum in CG Oncology, then scan a curated group of high potential healthcare and biotech names in our 19 high quality undiscovered gems.

The jump in CG Oncology after earnings puts you at a crossroads. You can either lean into the current optimism and pay up today, or wait for the next wobble before running the numbers on valuation.

Most Popular Narrative: 17% Undervalued

CG Oncology closed at $75.99 while the most followed narrative pegs fair value at about $91.08, so the recent earnings bounce still sits below that implied level and keeps attention squarely on how far cretostimogene can really reach.

The current valuation implies that the market is placing limited value on cretostimogene’s potential reach across more than 100,000 NMIBC patients per year and on CG Oncology’s cash position of about US$1.0 to US$1.1 billion with no debt and runway guided through 2029.

See why 2 investors see CG Oncology as 17% undervalued.

Result: Fair Value of $91.08 (UNDERVALUED)

Still, the CG Oncology story depends heavily on clean late stage trial outcomes and on payers accepting the pricing assumptions embedded in current analyst models.

Find out about the key risks to this CG Oncology narrative.

Next Steps

Mixed feelings about CG Oncology after this move are normal. Act promptly, review the numbers, and weigh both sides using the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond CG Oncology?

Do not stop with CG Oncology. Broaden your watchlist now, compare different risk and return profiles, and give yourself more than one way to be right.